Jake M. Holdreith

Jake M. Holdreith is a seasoned patent litigator and trial lawyer at Robins Kaplan LLP, where he also holds significant leadership roles as the Managing Partner of the Minneapolis office and a member of the firm's Executive Board. He leads the firm's Health and Life Sciences Industry Group, reflecting a key area of his practice. His expertise spans a variety of technology areas, including pharmaceuticals, medical devices, computer hardware and software, telecommunications, and electronics. Prior to joining Robins Kaplan in 2001, Mr. Holdreith practiced at Oppenheimer Wolff & Donnelly for approximately eleven years.

Mr. Holdreith maintains a balanced practice, representing both patent owners (plaintiffs) and accused infringers (defendants). While the provided data tracks one plaintiff-side appearance in Personal Audio LLC v. Apple Inc., resulting in an $8 million jury verdict that later settled for $12 million, his broader career includes numerous multi-million dollar jury verdicts for patent owners. These include a $34.7 million award in St. Clair Intellectual Property Consultants, Inc. v. Canon, Inc. and a $25 million award in St. Clair Intellectual Property Consultants, Inc. v. Sony Corp. He also secured a significant $467 million mRNA patent settlement for the University of Pennsylvania with BioNTech. On the defense side, he has achieved successful outcomes such as defense wins in Hatch-Waxman cases, including a successful defense of non-infringement after trial in Amgen v. Amneal and a judgment dismissing infringement claims in Purdue v. Collegium.

His experience extends to the Patent Trial and Appeal Board (PTAB), having been involved in multiple proceedings before the PTAB in cases such as Aquestive Therapeutics, Inc. v. BioDelivery Sciences Int'l, Inc. Mr. Holdreith is admitted to practice in Minnesota since 1990 and in New York, and he earned his law degree from The University of Iowa College of Law in 1990.